🇺🇸 FDA
Patent

US 8507463

Nucleotide analogue prodrug and the preparation thereof

granted A61KA61K31/675A61K9/0019

Quick answer

US patent 8507463 (Nucleotide analogue prodrug and the preparation thereof) held by BrightGene Bio-Medical Technology Co., Ltd. expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BrightGene Bio-Medical Technology Co., Ltd.
Grant date
Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/675, A61K9/0019, A61K9/0056, A61K9/2009